on news

footer news ticker

resources.

SUCCESSFUL PLACEMENT: SPRUCE BIOSCIENCES – CHIEF MEDICAL OFFICER

Nov 3, 2020 | Successful Placements, Suzanne Zebedee

Spruce Biosciences, a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, has appointed Dr. Rosh Dias to Chief Medical Officer. The appointment coincides with progress into Phase 2b clinical trials of tildacerfont in adult classic congenital adrenal hyperplasia (CAH).

“We are thrilled that Rosh is bringing to Spruce his strong industry and operational leadership experience as we advance our Phase 2b clinical trials of tildacerfont in CAH, and prepare to initiate Phase 2 clinical trials of tildacerfont in pediatric classic CAH and polycystic ovary syndrome in 2021,” said Richard King, Chief Executive Officer of Spruce Biosciences. “Rosh has deep experience in successful clinical development and commercialization of important treatments for patients with rare diseases, which will prove critical for our clinical development and registration strategies. Throughout his career, Rosh has shaped the understanding of novel treatments and their application, which will complement the capabilities of our existing team.”

Dr. Dias will oversee global clinical strategy and development for the company. He brings more than 20 years of experience in the pharmaceutical and biotechnology industries across multiple geographies, working to commercialize medicines for patients across multiple therapeutic areas, including the achievement of blockbuster status for several medicines. Dr. Dias joins Spruce most recently from Indivior, where he was the Chief Medical Officer for the past year. Prior to Indivior, Dr. Dias has had long tenures at both Amgen and Novartis. At Amgen, he was Vice President of Global Scientific Affairs, leading global scientific affairs spanning Amgen’s entire product portfolio and Vice President, Head of Global Medical and Scientific affairs at Onyx. Prior to Onyx, Dr. Dias spent a decade in various roles for Novartis, including senior Clinical Development and Medical Affairs roles in both the United States and Australia, where he led a variety of clinical development and medical affairs efforts with a focus on oncology, hematology, and rare diseases. Dr. Dias holds a Medical Doctor degree from Charing Cross and Westminster Medical School in the UK, and is a Member of the Royal College of Physicians through postgraduate qualification in Internal Medicine.

“I’m excited to join Spruce at this time of important growth and evolution for the company,” said Dr. Dias. “Spruce is a leader in the investigation of medicines in the field of rare endocrine disorders and has rapidly advanced tildacerfont into late-stage clinical development. I am pleased to work together with our experienced management team on the development of tildacerfont in adult classic CAH and other indications in our pipeline.”

Read the full press release published by Spruce Biosciences here.

ON Partners consultant Suzanne Zebedee, Ph.D. is proud to have partnered with Spruce Biosciences and Dr. Dias on this successful placement.  For more executive search work in Life Sciences, visit our recent successful placements here.


ABOUT SPRUCE BIOSCIENCES

 

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. The company has initiated a placebo-controlled, double-blind Phase 2b clinical trial in adult patients with classic CAH with poor disease control and anticipates topline results in the fourth quarter of 2021. The company also initiated a second placebo-controlled, double-blind Phase 2b clinical trial in adult patients with classic CAH with good disease control focused on glucocorticoid reduction and anticipates topline results in the first half of 2022. The company also plans to evaluate tildacerfont in pediatric classic CAH and polycystic ovary syndrome. For more information, please visit www.sprucebiosciences.com.


ABOUT ON PARTNERS

 

ON Partners propels an organization’s mission by building C-level and board leadership teams. Founded in 2006 by like-minded consultants as a values-driven alternative to the multi-service global firms they were leaving behind, ON delivers a better executive search experience. Named by Forbes as one of America’s Best Executive Recruiting Firms and to the Inc. 500/5000 Lists seven times, the firm is consistently ranked among the top 20 retained executive search firms in the U.S. For more information, see our results here.

Follow our work, updates and recent success on Twitter and LinkedIn.

Find our related successful placements of leading executives here.

Archives

+

connect with ON.

Bring ON executive search insights!
Sign up to receive thought leadership pieces, ON in the news, recent placements, quarterly updates and more.

ON resources.

ON in the news

ON PARTNERS PROMOTES THREE EXECUTIVE SEARCH CONSULTANTS

Danny Bolger and Jake Espenlaub named partners, Tindall Sewell appointed vice president at fastest-growing top-20 retained executive search firm CLEVELAND--(BUSINESS WIRE)--December 2, 2020 – ON Partners, the experience-driven retained executive search firm, today...

GRATITUDE TO THE ON COMMUNITY OF LEADERS IN 2020

On this Thanksgiving, we are grateful for our community of values-driven organizations and leaders, who have taken extraordinary measures in 2020 to support others   Connect With ON   November 24, 2020 - From product, service and time contributions to...

ON successful placements

SUCCESSFUL PLACEMENT: NEW WAVE DV – PRESIDENT

New Wave Design and Verification Appoints New President Connect With ON  (GLOBE NEWSWIRE) -- New Wave Design and Verification (New Wave DV), a leading provider of high-performance digital electronic interface solutions for the Defense/Aerospace market, is proud to...

SUCCESSFUL PLACEMENT: SOLARWINDS- VP, NORTH AMERICAN SALES

SolarWinds Appoints Jared Thomas to Vice President, North American Sales Connect With ON  SolarWinds (NYSE:SWI), a leading provider of powerful and affordable IT management software, has appointed Jared Thomas to Vice President, North American Sales. Jared Thomas...

a better experience gets recognized.

ON Partners named to the Weatherhead 100 Case Western University annual ranking of the region’s fastest growing companies
ON Partners named by Boston Business Journal’s Largest Executive Search Firms and Minneapolis/St. Paul Business Journal’s Twin Cities Largest Executive Search Firms
ON Partners six time Inc. winner by being name to the Inc. 500/5000 Lists and to the Inc. 5000 Hall of Fame
Hunt Scanlon names ON Partners executive search firm to the Private Equity Recruiting Power 75 list
Business Insider ON Partners Executive Recruiters
Fortune ON Partners Executive Search
Fast Company ON Partners Executive Search Consultants
ON Partners named by Forbes as one of America’s Best Executive Recruiting Firms

ANNAPOLIS • ATLANTA • BOSTON • CLEVELAND • DALLAS • MENLO PARK • MINNEAPOLIS • NEW YORK • SAN FRANCISCO

© Copyright 2019 On Partners. All Rights Reserved.